

Key diabetes, cardiac drugs to get cheaper

Rupali.Mukherjee@timesgroup.com

Mumbai: Widely-used anti-diabetic and cardiac medicines will become cheaper by as much as 35% over the next few weeks with the drug pricing regulator, National Pharmaceutical Pricing Authority, deciding to bring them under price control.

► India largest consumer of antibiotics, P 11

The drugs that will see a price cut include Gliclazide, Glimepiride, Glintir, Glibose, Amlodipine, Lisin, Lisartan and Rosuvastatin, Heparin and Ramipril.

► Continued on P 11

Consent given Mr. M.T
Rupali
14.7.14

T.D., NIC
Rupali
15.7.14

Pricing